Robert E Denroche
Overview
Explore the profile of Robert E Denroche including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
4249
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Antonova L, Paramanthan P, Falls T, Wedge M, Mayer J, Sekhon H, et al.
Cancers (Basel)
. 2024 Aug;
16(15).
PMID: 39123450
Pancreatic cancer has one of the worst prognoses among all malignancies and few available treatment options. Patient-derived xenografts can be used to develop personalized therapy for pancreatic cancer. Endoscopic ultrasound...
2.
Stossel C, Raitses-Gurevich M, Atias D, Beller T, Glick Gorman Y, Halperin S, et al.
Cancer Discov
. 2023 Jul;
13(8):1826-1843.
PMID: 37449843
Significance: glBRCA PDAC has a favorable response to platinum/PARP inhibition. However, most patients develop resistance. Additional treatment options for this unique subpopulation are needed. We generated model systems in PDXs...
3.
Perera S, Jang G, Wang Y, Kelly D, Allen M, Zhang A, et al.
Clin Cancer Res
. 2022 Oct;
28(23):5115-5120.
PMID: 36222851
Purpose: Modified FOLFIRINOX (mFFX) and gemcitabine/nab-paclitaxel (GnP) remain standard first-line options for patients with advanced pancreatic ductal adenocarcinoma (PDAC). Human equilibrative nucleoside transporter 1 (hENT1) was hypothesized to be a...
4.
Topham J, Tsang E, Karasinska J, Metcalfe A, Ali H, Kalloger S, et al.
Nat Commun
. 2022 Oct;
13(1):5941.
PMID: 36209277
Oncogenic KRAS mutations are absent in approximately 10% of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and may represent a subgroup of mPDAC with therapeutic options beyond standard-of-care cytotoxic chemotherapy....
5.
Wang Y, Cuggia A, Chen Y, Parent J, Stanek A, Denroche R, et al.
J Natl Compr Canc Netw
. 2022 Jun;
20(6):663-673.e12.
PMID: 35714671
Background: Individuals with a family history of pancreatic adenocarcinoma (PC) or with a germline mutation in a PC susceptibility gene are at increased risk of developing PC. These high-risk individuals...
6.
OKane G, Grunwald B, Jang G, Masoomian M, Picardo S, Grant R, et al.
Clin Cancer Res
. 2022 Jun;
28(12):2715.
PMID: 35694787
No abstract available.
7.
Golesworthy B, Wang Y, Tanti A, Pacis A, Romero J, Cuggia A, et al.
Front Oncol
. 2022 May;
12:860767.
PMID: 35547873
The immune contexture of pancreatic ductal adenocarcinoma (PDAC) is generally immunosuppressive. A role for immune checkpoint inhibitors (ICIs) in PDAC has only been demonstrated for the rare and hypermutated mismatch...
8.
Pham N, Radulovich N, Ibrahimov E, Martins-Filho S, Li Q, Pintilie M, et al.
Sci Rep
. 2021 May;
11(1):10619.
PMID: 34011980
Patient-derived xenograft (PDX) and their xenograft-derived organoid (XDO) models that recapitulate the genotypic and phenotypic landscape of patient cancers could help to advance research and lead to improved clinical management. ...
9.
Golan T, OKane G, Denroche R, Raitses-Gurevich M, Grant R, Holter S, et al.
Gastroenterology
. 2021 Feb;
160(6):2119-2132.e9.
PMID: 33524400
Background And Aims: Homologous recombination deficiency (HRD) in pancreatic ductal adenocarcinoma (PDAC), remains poorly defined beyond germline (g) alterations in BRCA1, BRCA2, and PALB2. Methods: We interrogated whole genome sequencing...
10.
Topham J, Karasinska J, Lee M, Csizmok V, Williamson L, Jang G, et al.
Clin Cancer Res
. 2020 Oct;
27(1):150-157.
PMID: 33051307
Purpose: RNA-sequencing-based subtyping of pancreatic ductal adenocarcinoma (PDAC) has been reported by multiple research groups, each using different methodologies and patient cohorts. "Classical" and "basal-like" PDAC subtypes are associated with...